Genomic Characteristics and the Potential Clinical Implications in Oligometastatic Non–Small Cell Lung Cancer
Cancer Research and Treatment · 2023
DOI: 10.4143/crt.2022.1315 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, 2023. Verfasst von Rongxin Liao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Center, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Municipal Natural Science Foundation of Chongqing, Hospital of Chongqing Medical University, Yuan Peng and the Project of Chongqing Technology Innovation and Application Development.
Abstract (Originalsprache)
Purpose
Oligometastatic non–small cell lung cancer (NSCLC) patients have been increasingly regarded as a distinct group that could benefit from local treatment to achieve a better clinical outcome. However, current definitions of oligometastasis are solely numerical, which are imprecise because of ignoring the biological heterogeneity caused by genomic characteristics. Our study aimed to profile the molecular alterations of oligometastatic NSCLC and elucidate its potential difference from polymetastasis.Materials and Methods We performed next-generation sequencing to analyze tumors and paired peripheral blood from 77 oligometastatic and 21 polymetastatic NSCLC patients to reveal their genomic characteristics and assess the genetic heterogeneity.
Results
We found ERBB2, ALK, MLL4, PIK3CB, and TOP2A were mutated at a significantly lower frequency in oligometastasis compared with polymetastasis. EGFR and KEAP1 alterations were mutually exclusive in oligometastatic group. More importantly, oligometastasis has a unique significant enrichment of apoptosis signaling pathway. In contrast to polymetastasis, a highly enriched COSMIC signature 4 and a special mutational process, COSMIC signature 14, were observed in the oligometastatic cohort. According to OncoKB database, 74.03% of oligometastatic NSCLC patients harbored at least one actionable alteration. The median tumor mutation burden of oligometastasis was 5.00 mutations/Mb, which was significantly associated with smoking, DNA damage repair genes, TP53 mutation, SMARCA4 mutation, LRP1B mutation, ABL1 mutation.
Conclusion
Our results shall help redefine oligometastasis beyond simple lesion enumeration that will ultimately improve the selection of patients with real oligometastatic state and optimize personalized cancer therapy for oligometastatic NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Center, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
- Geneplus-Beijing, Beijing, China.
- Chongqing Clinical Research Center for Geriatrics and Gerontology, Chongqing, China.
Förderung
- Municipal Natural Science Foundation of Chongqing
- Hospital of Chongqing Medical University
- Yuan Peng and the Project of Chongqing Technology Innovation and Application Development
- Chongqing Talents Program
Zitieren
APA
Liao, R., Chen, K., Li, J., He, H., Yi, G., Huang, M., Chen, R., Shen, L., Zhang, X., Xu, Z., Yang, Z., & Peng, Y. (2023). Genomic Characteristics and the Potential Clinical Implications in Oligometastatic Non–Small Cell Lung Cancer. Cancer Research and Treatment. https://doi.org/10.4143/crt.2022.1315
Vancouver
Liao R, Chen K, Li J, He H, Yi G, Huang M, et al. Genomic Characteristics and the Potential Clinical Implications in Oligometastatic Non–Small Cell Lung Cancer. Cancer Research and Treatment. 2023. doi:10.4143/crt.2022.1315
BibTeX
@article{Liao2023,
author = {Liao, Rongxin and Chen, Kehong and Li, Jinjin and He, Hengqiu and Yi, Guangming and Huang, Mingfeng and Chen, Rongrong and Shen, Lu and Zhang, Xiaoyue and Xu, Zaicheng and Yang, Zhenzhou and Peng, Yuan},
title = {Genomic Characteristics and the Potential Clinical Implications in Oligometastatic Non–Small Cell Lung Cancer},
journal = {Cancer Research and Treatment},
year = {2023},
doi = {10.4143/crt.2022.1315}
}
EUVIMED